Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus

Molecular Brain Research

Volumn 85, Issue 1-2, 2000, Pages 24-31

  Ohnuma, Tohru ^a,b,e   Tessler, Shosi ^b   Arai, Heii ^a   Faull, Richard L M ^c   McKenna, Peter J ^d   Emson, Piers C ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Juntendo University Hospital   (Japan)

Author keywords

Excitatory amino acid transporter; Glutamate; Hippocampus; In situ hybridization; Metabotropic glutamate receptor; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; EXCITATORY AMINO ACID; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATE TRANSPORTER; IONOTROPIC RECEPTOR; MESSENGER RNA; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID TRANSPORT; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; NEUROTRANSMISSION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBICULUM;

ACTINS; AGE FACTORS; AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BRAIN CHEMISTRY; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; HYDROGEN-ION CONCENTRATION; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; POSTMORTEM CHANGES; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, NEUROTRANSMITTER; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0034727878     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(00)00222-9     Document Type: Article

References (40)

1. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex
2. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: A detailed cellular in situ hybridization study
3. Metabotropic glutamate receptors: An original family of G protein-coupled receptors
4. Recent advances in the neuropathology of schizophrenia
5. The neuropathology of schizophrenia: Past and present
6. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers
7. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
8. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats
9. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
10. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
11. The phencyclidine-glutamate model of schizophrenia
12. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: A quantitative cellular in situ hybridisation study
13. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
14. Terminal coma affects messenger RNA detection in post mortem human temporal cortex
15. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia
16. Recent advances in the phencyclidine model of schizophrenia
17. Amelioration of negative symptoms in schizophrenia by glycine
18. Extensive postmortem stability of RNA from rat and human brain
19. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
20. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia
21. Tissue pH as an indicator of mRNA preservation in human post-mortem brain
22. 3[H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
23. Glutamatergic hypothesis of schizophrenia: Psychoses induced by phencyclidine and cortical-subcortical imbalance
24. Molecular cloning and the functional expression of two isoforms of human metabotropic glutamate receptor subtype 5
25. Molecular diversity of glutamate receptors and implications for brain function
26. 3H]kainic acid binding in the prefrontal cortex in schizophrenia
27. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia
28. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: Focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression
29. A magnetic resonance imaging study in first-episode disorganized-type patients with schizophrenia
30. Notes from the graveyard: Neuropathology and schizophrenia
31. Connections of the parahippocampal cortex. I. Cortical afferents
32. Metabotropic glutamate receptors in brain function and pathology
33. Evidence of glutamatergic deficiency in schizophrenia
34. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication
35. Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. I. Temporal lobe afferents
36. Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. II. Frontal lobe afferents
37. Neuroanatomic/neuropathologic correlates in schizophrenia
38. Glycine therapy of schizophrenia
39. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations